X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures
X4 Pharmaceuticals secured up to $150 million in senior debt financing from K2 HealthVentures, retiring its prior loan and extending its financial runway.
X4 Pharmaceuticals has secured a senior debt facility of up to $150 million with K2 HealthVentures, the company announced, marking a significant restructuring of its balance sheet as it advances a late-stage clinical program.
As part of the transaction, X4 retired its existing loan facility, eliminating prior debt obligations and replacing them with the new arrangement. The company said the financing is intended to support both corporate operations and commercial activities, broadening its financial flexibility at a critical development stage.
Read more Iantrek Reports 37% Eye Pressure Drop in Canaloplasty Trial →
The deal comes as X4 pushes forward with its Phase 3 4WARD clinical trial. The company expects to complete patient enrollment in that study by the end of 2026, with topline data anticipated in the first half of 2028. The trial timeline positions X4 for a potential regulatory milestone in the latter part of the decade, contingent on favorable results.
The K2 HealthVentures facility underscores continued private-market appetite for biopharmaceutical debt financing, particularly for companies with defined late-stage catalysts. For X4, the capital infusion provides a longer runway to reach the 4WARD data readout without immediate pressure to access equity markets.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
